Fluorescein Sodium And Benoxinate Hydrochloride Patent Expiration

Fluorescein Sodium And Benoxinate Hydrochloride is a drug owned by Bausch And Lomb Ireland Ltd. It is protected by 3 US drug patents filed from 2020 to 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 15, 2037. Details of Fluorescein Sodium And Benoxinate Hydrochloride's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842872 Fluorescein and benoxinate compositions
Nov, 2037

(12 years from now)

Active
US10632197 Fluorescein and benoxinate compositions
Nov, 2037

(12 years from now)

Active
US10293047 Fluorescein and benoxinate compositions
Nov, 2037

(12 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Fluorescein Sodium And Benoxinate Hydrochloride's patents.

Given below is the list of recent legal activities going on the following patents of Fluorescein Sodium And Benoxinate Hydrochloride.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 19 Apr, 2024 US10842872
Payment of Maintenance Fee, 4th Year, Large Entity 20 Sep, 2023 US10632197
Surcharge for Late Payment, Large Entity 17 Jan, 2023 US10293047
Payment of Maintenance Fee, 4th Year, Large Entity 17 Jan, 2023 US10293047
Maintenance Fee Reminder Mailed 09 Jan, 2023 US10293047
Recordation of Patent Grant Mailed 24 Nov, 2020 US10842872
Patent Issue Date Used in PTA Calculation 24 Nov, 2020 US10842872
Email Notification 05 Nov, 2020 US10842872
Issue Notification Mailed 04 Nov, 2020 US10842872
Dispatch to FDC 27 Oct, 2020 US10842872

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Fluorescein Sodium And Benoxinate Hydrochloride is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Fluorescein Sodium And Benoxinate Hydrochloride's family patents as well as insights into ongoing legal events on those patents.

Fluorescein Sodium And Benoxinate Hydrochloride's Family Patents

Fluorescein Sodium And Benoxinate Hydrochloride has patent protection in a total of 4 countries. It has a significant patent presence in the US with 62.5% of its patents being US patents. Click below to unlock the full patent family tree for Fluorescein Sodium And Benoxinate Hydrochloride.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Fluorescein Sodium And Benoxinate Hydrochloride's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 15, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Fluorescein Sodium And Benoxinate Hydrochloride Generics:

There are no approved generic versions for Fluorescein Sodium And Benoxinate Hydrochloride as of now.





About Fluorescein Sodium And Benoxinate Hydrochloride

Fluorescein Sodium And Benoxinate Hydrochloride is a drug owned by Bausch And Lomb Ireland Ltd. It is used for facilitating ocular procedures and examinations in patients requiring a disclosing agent with a topical ophthalmic anesthetic. Fluorescein Sodium And Benoxinate Hydrochloride uses Benoxinate Hydrochloride; Fluorescein Sodium as an active ingredient. Fluorescein Sodium And Benoxinate Hydrochloride was launched by Bausch Lomb Ireland in 2020.

Approval Date:

Fluorescein Sodium And Benoxinate Hydrochloride was approved by FDA for market use on 09 March, 2020.

Active Ingredient:

Fluorescein Sodium And Benoxinate Hydrochloride uses Benoxinate Hydrochloride; Fluorescein Sodium as the active ingredient. Check out other Drugs and Companies using Benoxinate Hydrochloride; Fluorescein Sodium ingredient

Treatment:

Fluorescein Sodium And Benoxinate Hydrochloride is used for facilitating ocular procedures and examinations in patients requiring a disclosing agent with a topical ophthalmic anesthetic.

Dosage:

Fluorescein Sodium And Benoxinate Hydrochloride is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.4%;0.3% SOLUTION/DROPS Prescription OPHTHALMIC